Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Page 1
Isolated distal deep vein thrombosis: What have we learnt from the OPTIMEV study?
Galanaud JP, Sevestre MA, Pernod G, Vermorel C, Rolland C, Soudet S, Laroche JP, Bosson JL; OPTIMEV-SFMV investigators. Galanaud JP, et al. Among authors: pernod g. J Med Vasc. 2023 Feb;48(1):3-10. doi: 10.1016/j.jdmv.2023.03.003. Epub 2023 Apr 17. J Med Vasc. 2023. PMID: 37120268
. - Deep calf vein and muscular DVT share the same risk factors, short and long-term prognoses. - In patients without history of cancer, risk of unknown cancer is similar in patients with a first distal or proximal DVT. - After 3years and once anticoagulation has been stop …
. - Deep calf vein and muscular DVT share the same risk factors, short and long-term prognoses. - In patients without history of canc …
Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin.
Bistervels IM, Bavalia R, Beyer-Westendorf J, Ten Cate-Hoek AJ, Schellong SM, Kovacs MJ, Falvo N, Meijer K, Stephan D, Boersma WG, Ten Wolde M, Couturaud F, Verhamme P, Brisot D, Kahn SR, Ghanima W, Montaclair K, Hugman A, Carroll P, Pernod G, Sanchez O, Ferrari E, Roy PM, Sevestre-Pietri MA, Birocchi S, Wik HS, Hutten BA, Coppens M, Naue C, Grosso MA, Shi M, Lin Y, Quéré I, Middeldorp S; Hokusai PTS Investigators. Bistervels IM, et al. Among authors: pernod g. Res Pract Thromb Haemost. 2022 Jul 1;6(5):e12748. doi: 10.1002/rth2.12748. eCollection 2022 Jul. Res Pract Thromb Haemost. 2022. PMID: 35992565 Free PMC article.
BACKGROUND: Postthrombotic syndrome (PTS) is a long-term complication after deep vein thrombosis (DVT) and can affect quality of life (QoL). ...OBJECTIVES: To compare the prevalence of PTS after acute DVT and the long-term QoL following DVT between patients treated …
BACKGROUND: Postthrombotic syndrome (PTS) is a long-term complication after deep vein thrombosis (DVT) and can affect quality of life …
Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin.
Bavalia R, Bistervels IM, Boersma WG, Quere I, Brisot D, Falvo N, Stephan D, Couturaud F, Schellong S, Beyer-Westendorf J, Montaclair K, Ghanima W, Ten Wolde M, Coppens M, Ferrari E, Sanchez O, Carroll P, Roy PM, Kahn SR, Meijer K, Birocchi S, Kovacs MJ, Hugman A, Ten Cate H, Wik H, Pernod G, Sevestre-Pietri MA, Grosso MA, Shi M, Lin Y, Hutten BA, Verhamme P, Middeldorp S; Hokusai post‐PE study investigators. Bavalia R, et al. Among authors: pernod g. Res Pract Thromb Haemost. 2021 Jul 14;5(5):e12566. doi: 10.1002/rth2.12566. eCollection 2021 Jul. Res Pract Thromb Haemost. 2021. PMID: 34278193 Free PMC article.
BACKGROUND: Long-term sequelae of acute pulmonary embolism (PE) include decreased quality of life (QoL). ...CONCLUSION: Our findings indicate that patients with an index PE treated with edoxaban or warfarin have a similar long-term QoL. Since our study was a follow- …
BACKGROUND: Long-term sequelae of acute pulmonary embolism (PE) include decreased quality of life (QoL). ...CONCLUSION: Our findings …
Compliance with Early Long-Term Prophylaxis Guidelines for Severe Hemophilia A.
Saultier P, Guillaume Y, Demiguel V, Berger C, Borel-Derlon A, Claeyssens S, Harroche A, Oudot C, Rafowicz A, Trossaert M, Wibaut B, Vinciguerra C, Boucekine M, Baumstarck K, Meunier S, Calvez T, Chambost H; FranceCoag PUPs / CoMETH Prophylaxis Study Group; Hemophilia Treatment Centers of Paris-Necker. Saultier P, et al. J Pediatr. 2021 Jul;234:212-219.e3. doi: 10.1016/j.jpeds.2021.02.071. Epub 2021 Mar 4. J Pediatr. 2021. PMID: 33676933 Clinical Trial.
Earlier birth year (OR 0.5, 95% CI 0.3-0.8, P = .010 for birth years 2005-2009 vs 2000-2004) and age at first factor replacement (OR 1.9 for each additional year, 95% CI 1.2-3.0, P = .005) were significantly associated with "long-term prophylaxis guideline co …
Earlier birth year (OR 0.5, 95% CI 0.3-0.8, P = .010 for birth years 2005-2009 vs 2000-2004) and age at first factor replaceme …
Epidemiology and 3-year outcomes of combined oral contraceptive-associated distal deep vein thrombosis.
Galanaud JP, Sevestre MA, Pernod G, Genty C, Richaud C, Rolland C, Weber L, Kahn SR, Quéré I, Bosson JL; OPTIMEV‐SFMV Investigators. Galanaud JP, et al. Among authors: pernod g. Res Pract Thromb Haemost. 2020 Sep 15;4(7):1216-1223. doi: 10.1002/rth2.12409. eCollection 2020 Oct. Res Pract Thromb Haemost. 2020. PMID: 33134787 Free PMC article.
In women of childbearing age, a frequent triggering risk factor is the use of combined oral contraceptive (COC) pills. However, data on the epidemiology and long-term outcomes of COC-associated distal DVT are lacking. OBJECTIVES: To assess the epidemiology and long-term …
In women of childbearing age, a frequent triggering risk factor is the use of combined oral contraceptive (COC) pills. However, data on the …
Long-term outcomes of isolated superficial vein thrombosis in patients with active cancer.
Galanaud JP, Blaise S, Sevestre MA, Terrisse H, Pernod G, Gaillard C, Genty C, Monreal M, Rabah Y, Kahn SR, Quéré I, Bosson JL; OPTIMEV-SFMV investigators. Galanaud JP, et al. Among authors: pernod g. Thromb Res. 2018 Nov;171:179-186. doi: 10.1016/j.thromres.2018.04.013. Epub 2018 Apr 20. Thromb Res. 2018. PMID: 29789147 Clinical Trial.
Prevention and treatment of cancer-associated thrombosis in France: A national survey among vascular disease and supportive care specialists.
Mahé I, Scotté F, Rey JB, Elalamy I, Lamblin A, Mayeur D, Pernod G; AFSOS (French-speaking Association for Supportive Care in Oncology), SFMV (French Society for Vascular Medicine). Mahé I, et al. Among authors: pernod g. J Med Vasc. 2017 Oct;42(5):255-262. doi: 10.1016/j.jdmv.2017.07.002. Epub 2017 Sep 4. J Med Vasc. 2017. PMID: 28964384
BACKGROUND/AIM: Long-term use of low-molecular-weight heparins (LMWH) for the treatment of cancer-associated thrombosis (CAT) has been well-established. ...
BACKGROUND/AIM: Long-term use of low-molecular-weight heparins (LMWH) for the treatment of cancer-associated thrombosis (CAT) has bee …
Long-term risk of venous thromboembolism recurrence after isolated superficial vein thrombosis.
Galanaud JP, Sevestre MA, Pernod G, Kahn SR, Genty C, Terrisse H, Brisot D, Gillet JL, Quéré I, Bosson JL. Galanaud JP, et al. Among authors: pernod g. J Thromb Haemost. 2017 Jun;15(6):1123-1131. doi: 10.1111/jth.13679. Epub 2017 May 5. J Thromb Haemost. 2017. PMID: 28317330 Free article.
Essentials Long-term risk of recurrence of isolated superficial vein thrombosis (SVT) is under-studied. ...Click to hear Dr Decousus' perspective on superficial vein thrombosis SUMMARY: Background Isolated superficial vein thrombosis (iSVT) (without concomitant deep vein t …
Essentials Long-term risk of recurrence of isolated superficial vein thrombosis (SVT) is under-studied. ...Click to hear Dr Decousus' …
Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study.
Rodger MA, Le Gal G, Anderson DR, Schmidt J, Pernod G, Kahn SR, Righini M, Mismetti P, Kearon C, Meyer G, Elias A, Ramsay T, Ortel TL, Huisman MV, Kovacs MJ; REVERSE II Study Investigators. Rodger MA, et al. Among authors: pernod g. BMJ. 2017 Mar 17;356:j1065. doi: 10.1136/bmj.j1065. BMJ. 2017. PMID: 28314711 Free PMC article. Clinical Trial.
Objective To prospectively validate the HERDOO2 rule (Hyperpigmentation, Edema, or Redness in either leg; D-dimer level 250 mug/L; Obesity with body mass index 30; or Older age, 65 years), which states that women with none or one of the criteria can safely discontinue anticoagula …
Objective To prospectively validate the HERDOO2 rule (Hyperpigmentation, Edema, or Redness in either leg; D-dimer level 250 mug/L; Obesity w …
26 results